GILD · NASDAQ
Gilead Sciences, Inc.
$156.04 -1.11 (-0.71%)
Company overview
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs in the United States, Europe, and internationally. The company offers treatments for HIV/AIDS including Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla; Veklury for coronavirus disease 2019; and liver disease treatments such as Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Gilead also provides oncology and cell therapy products including Yescarta, Tecartus, Trodelvy, and Zydelig for hematology patients; Letairis for pulmonary arterial hypertension; Ranexa for chronic angina; and AmBisome for serious invasive fungal infections.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Market cap
- $193B
- Employees
- 17,600
- Headquarters
- Foster City, CA
- Website
- gilead.com
- CEO
- Daniel O'Day
- Listed
- January 22, 1992
- P/E
- 21.03
- Dividend yield
- 2.22%
Company financials
- Revenue
- $29.7B
- Gross profit
- $23.6B
- Operating income
- $11.4B
- EBITDA
- $13.3B
- Net income
- $9.2B
- EPS
- $7.42
- Total assets
- $56.3B
- Total debt
- $22.2B
- Gross margin
- 79.35%
- Net margin
- 30.99%
- Earnings yield
- 4.76%
Showing FY 2025
GILD
1D
NASDAQ
O154.24H157.42L153.00C157.19+3.62 (+2.36%)Vol6.21M